Teaghrelin protected dopaminergic neurons in MPTP-induced Parkinson's disease animal model by promoting PINK1/Parkin-mediated mitophagy and AMPK/SIRT1/PGC1-α-mediated mitochondrial biogenesis
- PMID: 38622810
- DOI: 10.1002/tox.24275
Teaghrelin protected dopaminergic neurons in MPTP-induced Parkinson's disease animal model by promoting PINK1/Parkin-mediated mitophagy and AMPK/SIRT1/PGC1-α-mediated mitochondrial biogenesis
Abstract
Mitochondrial dysfunction, a common cellular hallmark in both familial and sporadic forms of Parkinson's disease (PD), is assumed to play a significant role in pathologic development and progression of the disease. Teaghrelin, a unique bioactive compound in some oolong tea varieties, has been demonstrated to protect SH-SY5Y cells against 1-methyl-4-phenylpyridinium induced neurotoxicity by binding to the ghrelin receptor to activate the AMPK/SIRT1/PGC-1α pathway. In this study, an animal model was established using a neurotoxin, 1-methyl-4phenyl-1,2,3,6-tetrahydropyridine (MPTP), a byproduct of a prohibited drug, to evaluate the oral efficacy of teaghrelin on PD by monitoring motor dysfunction of mice in open field, pole, and bean walking tests. The results showed that MPTP-induced motor dysfunction of mice was significantly attenuated by teaghrelin supplementation. Tyrosine hydroxylase and dopamine transporter protein were found reduced in the striatum and midbrain of MPTP-treated mice, and significantly mitigated by teaghrelin supplementation. Furthermore, teaghrelin administration enhanced mitophagy and mitochondria biogenesis, which maintained cell homeostasis and prevented the accumulation of αSyn and apoptosis-related proteins. It seemed that teaghrelin protected dopaminergic neurons in MPTP-treated mice by increasing PINK1/Parkin-mediated mitophagy and AMPK/SIRT1/PGC-1α-mediated mitochondria biogenesis, highlighting its potential therapeutic role in maintaining dopaminergic neurons function in PD. Mitochondrial dysfunction, a common cellular hallmark in both familial and sporadic forms of Parkinson's disease (PD), is assumed to play a significant role in pathologic development and progression of the disease. Teaghrelin, a unique bioactive compound in some oolong tea varieties, has been demonstrated to protect SH-SY5Y cells against 1-methyl-4-phenylpyridinium induced neurotoxicity by binding to the ghrelin receptor to activate the AMPK/SIRT1/PGC-1α pathway. In this study, an animal model was established using a neurotoxin, 1-methyl-4phenyl-1,2,3,6-tetrahydropyridine (MPTP), a byproduct of a prohibited drug, to evaluate the oral efficacy of teaghrelin on PD by monitoring motor dysfunction of mice in open field, pole, and bean walking tests. The results showed that MPTP-induced motor dysfunction of mice was significantly attenuated by teaghrelin supplementation. Tyrosine hydroxylase and dopamine transporter protein were found reduced in the striatum and midbrain of MPTP-treated mice, and significantly mitigated by teaghrelin supplementation. Furthermore, teaghrelin administration enhanced mitophagy and mitochondria biogenesis, which maintained cell homeostasis and prevented the accumulation of αSyn and apoptosis-related proteins. It seemed that teaghrelin protected dopaminergic neurons in MPTP-treated mice by increasing PINK1/Parkin-mediated mitophagy and AMPK/SIRT1/PGC-1α-mediated mitochondria biogenesis, highlighting its potential therapeutic role in maintaining dopaminergic neurons function in PD.
Keywords: Parkinson's disease; bioactive compounds; mitochondria biogenesis; mitophagy; neurotoxicity; teaghrelin.
© 2024 Wiley Periodicals LLC.
Similar articles
-
Ghrelin protects against rotenone-induced cytotoxicity: Involvement of mitophagy and the AMPK/SIRT1/PGC1α pathway.Neuropeptides. 2021 Jun;87:102134. doi: 10.1016/j.npep.2021.102134. Epub 2021 Feb 19. Neuropeptides. 2021. PMID: 33639357
-
Teaghrelin Protects SH-SY5Y Cells against MPP+-Induced Neurotoxicity through Activation of AMPK/SIRT1/PGC-1α and ERK1/2 Pathways.Nutrients. 2020 Nov 28;12(12):3665. doi: 10.3390/nu12123665. Nutrients. 2020. PMID: 33260513 Free PMC article.
-
Cytarabine prevents neuronal damage by enhancing AMPK to stimulate PINK1 / Parkin-involved mitophagy in Parkinson's disease model.Eur J Pharmacol. 2024 Aug 15;977:176743. doi: 10.1016/j.ejphar.2024.176743. Epub 2024 Jun 14. Eur J Pharmacol. 2024. PMID: 38880222
-
Pharmacological approaches to enhance mitochondrial biogenesis: focus on PGC-1Α, AMPK, and SIRT1 in cellular health.Mol Biol Rep. 2025 Feb 28;52(1):270. doi: 10.1007/s11033-025-10368-8. Mol Biol Rep. 2025. PMID: 40019682
-
Alpha-Synuclein Effects on Mitochondrial Quality Control in Parkinson's Disease.Biomolecules. 2024 Dec 22;14(12):1649. doi: 10.3390/biom14121649. Biomolecules. 2024. PMID: 39766356 Free PMC article. Review.
Cited by
-
The role of redox signaling in mitochondria and endoplasmic reticulum regulation in kidney diseases.Arch Toxicol. 2025 May;99(5):1865-1891. doi: 10.1007/s00204-025-04041-z. Epub 2025 Apr 11. Arch Toxicol. 2025. PMID: 40214774 Free PMC article. Review.
-
Ketogenic Metabolism in Neurodegenerative Diseases: Mechanisms of Action and Therapeutic Potential.Metabolites. 2025 Jul 31;15(8):508. doi: 10.3390/metabo15080508. Metabolites. 2025. PMID: 40863128 Free PMC article. Review.
-
Study insights in the role of PGC-1α in neurological diseases: mechanisms and therapeutic potential.Front Aging Neurosci. 2025 Feb 12;16:1454735. doi: 10.3389/fnagi.2024.1454735. eCollection 2024. Front Aging Neurosci. 2025. PMID: 40012862 Free PMC article. Review.
-
Cardiac diastolic dysfunction by cigarette smoking is associated with mitochondrial integrity in the heart.FASEB J. 2024 Jul 31;38(14):e23826. doi: 10.1096/fj.202400858R. FASEB J. 2024. PMID: 39046373 Free PMC article.
-
HIIT versus MICT in MASLD: mechanisms mediated by gut-liver axis crosstalk, mitochondrial dynamics remodeling, and adipokine signaling attenuation.Lipids Health Dis. 2025 Apr 16;24(1):144. doi: 10.1186/s12944-025-02565-y. Lipids Health Dis. 2025. PMID: 40241065 Free PMC article.
References
REFERENCES
-
- Srinivasan E, Chandrasekhar G, Chandrasekar P, et al. Alpha‐synuclein aggregation in Parkinson's disease. Front Med. 2021;8:736978. doi:10.3389/fmed.2021.736978
-
- Haque ME, Akther M, Azam S, et al. Targeting α‐synuclein aggregation and its role in mitochondrial dysfunction in Parkinson's disease. Br J Pharmacol. 2022;179(1):23‐45. doi:10.1111/bph.15684
-
- Cheng HC, Ulane CM, Burke RE. Clinical progression in Parkinson disease and the neurobiology of axons. Ann Neurol. 2010;67(6):715‐725. doi:10.1002/ana.21995
-
- Dorsey ER, Sherer T, Okun MS, Bloem BR. The emerging evidence of the Parkinson pandemic. J Parkinsons Dis. 2018;8(s1):S3‐s8. doi:10.3233/jpd‐181474
-
- Ou Z, Pan J, Tang S, et al. Global trends in the incidence, prevalence, and years lived with disability of Parkinson's disease in 204 countries/territories from 1990 to 2019. Front Public Health. 2021;9:776847. doi:10.3389/fpubh.2021.776847
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources